Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2025 Earnings Call Transcript February 12, 2026 Karyopharm Therapeutics Inc.

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the ...

Roivant Sciences Ltd (ROIV) showcases promising pipeline progress and a strong cash position amidst ongoing challenges and opportunities.

Discusses 2026 Clinical Pipeline Outlook and Anticipated Trial Updates February 2, 2026 7:01 PM ESTCompany ParticipantsGary ...

Lund, Sweden - February 10, 2026 -Active Biotech (NASDAQ Stockholm: ACTI) today received positive feedback on its clinical proof-of-concept trial with tasquinimod in myelofibrosis. The study will now ...

Laseroptek America Corp. (“Laseroptek America” or “LOA”) today announced that it has filed counterclaims and third-party claims against Strata Skin Sciences, Inc. (“Strata”) and its Chief Executive ...

Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Call Transcript February 10, 2026 Incyte Corporation misses on earnings expectations. Reported EPS is $1.46 EPS, expectations were $1.94. Operator: ...

Q4 2025 Earnings Call February 10, 2026 8:00 AM ESTCompany ParticipantsAlexis Smith - Vice President & Head of ...

As a next-generation selective S1P receptor modulator, VELSIPITY® offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily ...

Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...